New studies from the Abramson Cancer Center at the University of Pennsylvania uses a large, real-world dataset to demonstrate there is a modest but consistent survival benefit associated with adding bevacizumab to carboplatin-pemetrexed when treating advanced non-squamous non-small cell lung cancer. The results were published in the May 2019 issue of the Journal of the National Comprehensive Cancer Network.
This combination is already a common clinical practice, but there has never been a randomized prospective clinical trial determining whether adding bevacizumab confers any survival benefit.
“Our results suggest that in patients with a contraindication to immunotherapy, such as connective tissue, rheumatologic, or interstitial lung disease, bevacizumab may be a reasonable alternative, instead of pembrolizumab, to add to carboplatin-pemetrexed,” lead author Stephen J. Bagley, assistant professor of Hematology-Oncology, Abramson Cancer Center, said in a statement.
“Many oncologists were already using carboplatin-pemetrexed-bevacizumab for patients with advanced non-squamous NSCLC, but this study suggests there is indeed an improvement in overall survival when bevacizumab is added. What’s more, I was surprised to learn that the survival benefit of bevacizumab persisted even in older patients and after adjusting for brain metastases, hemoptysis, and anticoagulation use.”
The retrospective study used nationally representative electronic health record data from Flatiron Health (part of Roche).
Stephen J. Bagley, MD, MSCE